Loading...
Loading...
Rodman & Renshaw maintained its ARIAD Pharmaceuticals
ARIA Market Outperform rating and $18 price target in a research report published today.
In the report, Rodman & Renshaw stated, "We continue to believe investors have not realized the full economic potential of ponatinib, or that ARIA likely will have two approved products on the market in the US and EU by 2013 with another drug in a pivotal trial."
Shares of ARIAD Pharmaceuticals were trading at $14.42 at the time of posting, down 4.88% from Monday's market close.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We simplify the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in